<DOC>
	<DOCNO>NCT02871492</DOCNO>
	<brief_summary>Randomized , double-blind , multi-center , three arm parallel group , comparative trial ass pritelivir ointment safety efficacy , ie , proportion subject non-ulcerative lesion , adult subject recurrent herpes labialis ( RHL ) comparison placebo Zovirax® Cream . The start treatment trial medication initiate subject within one hour notice first sign symptom ( eg , prodrome ) recurrence herpes labialis . Trial medication apply affected area 5 time daily 4 day . After self-initiation treatment trial medication subject assess daily Investigator complete heal maximum 13 day . Subjects document application trial medication status lesion diary . There also blood sampling , ECG measurement physical examination perform investigational site .</brief_summary>
	<brief_title>Trial Efficacy Safety Pritelivir Ointment Treatment Labial Herpes</brief_title>
	<detailed_description />
	<mesh_term>Herpes Labialis</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Healthy men woman ethnic group age ≥18 year ; Subjects experience ≥4 recurrence herpes labialis previous 12months period ; Subjects experience prodromal symptom least 50 % recurrent Herpes labialis ( rHL ) episodes developed ulcerative lesion progress vesicle , ulcer , crust stage least 50 % episode ; Willingness use topical application ( cosmetic , lip balm , sunscreens etc… ) trial medication area lesion development start prodromal symptom complete healing ; Willingness use systemic topical antiHerpes Simplex Virus ( HSV ) agent trial participation include prescription OTC product ; Willingness use systemic , antiinflammatory analgesic agent start prodromal symptom heal ; Willingness refrain mechanical disruption ( ie , scrub , lance , shave ) prodromal area lesion start treatment trial medication end trial participation ; Women child bear potential male must use adequate contraception ; Subject must give write informed consent . Subjects current lesion may enrol , must treat lesion present screening/randomization trial medication ; instruct wait next subsequent lesion Known intolerance pritelivir ointment ingredient ; Known intolerance Zovirax® Cream ingredient ( ie , acyclovir , cetostearyl alcohol , mineral oil , poloxamer 407 , propylene glycol , sodium lauryl sulfate , white petrolatum ) valacyclovir ; Any skin condition could interfere assessment herpes labialis recurrence ( eg , eczema , psoriasis , acne etc… ) Any condition opinion Investigator would interfere successful completion clinical trial Pregnant and/or breastfeed woman Participation investigational drug trial within last 30 day randomization clinical trial Previous treatment pritelivir tablet Previous participation HSV vaccination Trial unless receive placebo . Clinically relevant ECG abnormality ( eg , QTc accord Fridericia : QTcF &gt; 450 m male QTcF &gt; 470 m female ; PR &gt; 220 m ) screening . Clinically relevant abnormality laboratory index screen opinion investigator might impact safety evaluability subject . Known chronic infection opinion investigator might impact safety evaluability subject . Evidence active malignancy immunodeficiency disease , require chronic use immunosuppressive drug ( eg , systemic steroid ) topical steroid , chronically use antiviral medication activity HSV . HIV positive base screening lab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>